OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.

Conditions

Diabetes

Keywords

Diabetes, Benchmarking, quality of patient care, Diabetic Population

Brief summary

Demonstrate that the use of benchmarking improves quality of patient care, in particular the control of diabetes, lipids and blood pressure, by determining the percentage of patients in the benchmarking group achieving pre-set targets for HbA1c 14,18, LDL-cholesterol16,18 and Systolic Blood Pressure17,18 versus control group (non-benchmarking group) after 12 months of follow-up.

Tsimihodimos V, Kostapanos MS, Moulis A, Nikas N, Elisaf MS.

2015-10-014 citations

10.1177/2042018815592803

Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece.

Kostapanos MS, Tsimihodimos V, Elisaf MS, Tzouvelekis E, Nikas N.

2014-02-013 citations

10.4239/wjd.v5.i1.76

Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries.

Hermans MP, Brotons C, Elisaf M, Michel G, Muls E, Nobels F, (for the OPTIMISE (OPtimal Type 2 dIabetes Management Including benchmarking and Standard trEatment) International Steering Committee).

2012-05-1721 citations

10.1177/2047487312449414

Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus.

Nobels F, Debacker N, Brotons C, Elisaf M, Hermans MP, Michel G, Muls E, OPTIMISE (OPtimal Type 2 dIabetes Management Including benchmarking and Standard trEatment) International Steering Committee.

2011-09-2210 citations

10.1186/1475-2840-10-82

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Provision of informed Consent * Patients suffering from diabetes type II, insulin dependent or not insulin dependent.

Exclusion criteria

* Type I diabetes * Pregnancy diabetes * Hospitalisation, as this is a primary care study * Patients who are member of the Belgian Diabetes Convention

Design outcomes

Primary

Measure	Time frame
HbA1c, LDL-cholesterol, Systolic Blood Pressure	Visit 1; Visit 2 (after approximately 4 months after visit 1); Visit 3 (after approximately 8 months after visit 1); Visit 4 (after approximately 12 months after visit 1)

Secondary

Measure	Time frame
Glycaemia, Triglycerides, Total and HDL-Cholesterol, Diastolic Blood Pressure, Waist circumference, Smoking habits, Microalbuminuria, Body Mass Index, Physical activity (Rating scale and step counter), Degree of ophthalmic control and dietary advice	Visit 1Visit 2 (after approximately 4 months after visit 1)Visit 3 (after approximately 8 months after visit 1)Visit 4 (after approximately 12 months after visit 1)

Countries

Belgium, Greece, Luxembourg, Portugal, Spain, United Kingdom

Outcome results